{"title":"在宫颈癌治疗中,48 小时单次应用多点近距离放射治疗与每周连续应用近距离放射治疗相比,可加快总体治疗时间--基于次大陆的多机构非劣效性真实世界研究","authors":"","doi":"10.1016/j.ijrobp.2024.07.015","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose/Objective(s)</h3><div>Standard practice entails employing multifractionated high-dose-rate (HDR) BT, administered in 3 to 4 sessions over 3 weeks post Chemoradiation, keeping overall treatment time < 56 days. Mono-application fractionated brachytherapy accelerates the treatment timeline without escalating acute or late toxicities. Recent progress in image-guided brachytherapy in cervical cancer facilitates the attainment of optimal dose volume parameters for both the target and organs at risk. This is the first multinational, multi-institutional study comparing outcomes and toxicity of mono-application fractionated brachytherapy versus multiple-application brachytherapy in carcinoma cervix.</div></div><div><h3>Materials/Methods</h3><div>Enrolled 401 eligible patients with confirmed cervical cancer, FIGO stages IIA-IVA, intended definitive chemoradiation. Patients post 45-50 Gy external radiation with cisplatin either received mono-application fractionated brachytherapy or multiple-application for interstitial or intracavitary BT. Rectal and bladder doses were strictly maintained within 50% of prescription dose with adequate dosing to high-risk target volume. Demographic data, stage, histology, external radiation dose, brachytherapy dose and fractionation, D2 cc doses to bladder, rectum were recorded. Disease free survival and overall survival at 3 years were obtained along with data on acute and long-term bladder and rectal toxicities.</div></div><div><h3>Results</h3><div>Four hundred one patients, 203 received multiple applications spaced over 3 weeks and 198 received single application multiple deliveries < 48 hours. All patients underwent Intracavitary or Interstitial BT with most common fractionation of 7 Gyx3 or equivalent. Rectal and bladder 2 cc doses were 45% +/- 12% of prescription dose. HRCTV coverage of D90 of 95+/-7 was achieved in all cases. With a median follow up of 36 months (range = 22-37), 3 year disease-free was 0.78 and 0.76, The <em>P</em> value of 0.98 (> 0.05), showed difference in DFS between the two groups was not statistically significant. The 3-year overall survival was 0.72 and 0.71, <em>P</em> value of 0.1 (> 0.05), again statistically insignificant. Cox regression model analysis showed stage wise DFS and OS difference between the groups weren’t statistically significant, hence proving the non-inferiority. The 3 year Grade 2 or more bladder and rectal toxicity has been reported in 2.3% and 4.1% in mono application group and 2.9% and 6.3% of multi-application group, statistically insignificant, confirming the credibility of our approach.</div></div><div><h3>Conclusion</h3><div>Our study lays the foundation for a comprehensive investigation into the outcomes and efficacy of mono-application fractionated brachytherapy being non inferior to multiple-application with respect to outcomes and toxicity, providing valuable insights into the management of cervical cancer with reduced overall treatment time and superior resource management. Strict constraints to OARs and accuracy of image guided brachytherapy techniques, long term toxicity could be minimized.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acceleration of Overall Treatment Time by Mono-Application Multifractionated Brachytherapy over 48 Hours vs. Sequential Weekly Application Brachytherapy in Carcinoma Cervix – Multi-Institutional, Subcontinent Based Real World Non-Inferiority Study\",\"authors\":\"\",\"doi\":\"10.1016/j.ijrobp.2024.07.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose/Objective(s)</h3><div>Standard practice entails employing multifractionated high-dose-rate (HDR) BT, administered in 3 to 4 sessions over 3 weeks post Chemoradiation, keeping overall treatment time < 56 days. Mono-application fractionated brachytherapy accelerates the treatment timeline without escalating acute or late toxicities. Recent progress in image-guided brachytherapy in cervical cancer facilitates the attainment of optimal dose volume parameters for both the target and organs at risk. This is the first multinational, multi-institutional study comparing outcomes and toxicity of mono-application fractionated brachytherapy versus multiple-application brachytherapy in carcinoma cervix.</div></div><div><h3>Materials/Methods</h3><div>Enrolled 401 eligible patients with confirmed cervical cancer, FIGO stages IIA-IVA, intended definitive chemoradiation. Patients post 45-50 Gy external radiation with cisplatin either received mono-application fractionated brachytherapy or multiple-application for interstitial or intracavitary BT. Rectal and bladder doses were strictly maintained within 50% of prescription dose with adequate dosing to high-risk target volume. Demographic data, stage, histology, external radiation dose, brachytherapy dose and fractionation, D2 cc doses to bladder, rectum were recorded. Disease free survival and overall survival at 3 years were obtained along with data on acute and long-term bladder and rectal toxicities.</div></div><div><h3>Results</h3><div>Four hundred one patients, 203 received multiple applications spaced over 3 weeks and 198 received single application multiple deliveries < 48 hours. All patients underwent Intracavitary or Interstitial BT with most common fractionation of 7 Gyx3 or equivalent. Rectal and bladder 2 cc doses were 45% +/- 12% of prescription dose. HRCTV coverage of D90 of 95+/-7 was achieved in all cases. With a median follow up of 36 months (range = 22-37), 3 year disease-free was 0.78 and 0.76, The <em>P</em> value of 0.98 (> 0.05), showed difference in DFS between the two groups was not statistically significant. The 3-year overall survival was 0.72 and 0.71, <em>P</em> value of 0.1 (> 0.05), again statistically insignificant. Cox regression model analysis showed stage wise DFS and OS difference between the groups weren’t statistically significant, hence proving the non-inferiority. The 3 year Grade 2 or more bladder and rectal toxicity has been reported in 2.3% and 4.1% in mono application group and 2.9% and 6.3% of multi-application group, statistically insignificant, confirming the credibility of our approach.</div></div><div><h3>Conclusion</h3><div>Our study lays the foundation for a comprehensive investigation into the outcomes and efficacy of mono-application fractionated brachytherapy being non inferior to multiple-application with respect to outcomes and toxicity, providing valuable insights into the management of cervical cancer with reduced overall treatment time and superior resource management. Strict constraints to OARs and accuracy of image guided brachytherapy techniques, long term toxicity could be minimized.</div></div>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0360301624007776\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624007776","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Acceleration of Overall Treatment Time by Mono-Application Multifractionated Brachytherapy over 48 Hours vs. Sequential Weekly Application Brachytherapy in Carcinoma Cervix – Multi-Institutional, Subcontinent Based Real World Non-Inferiority Study
Purpose/Objective(s)
Standard practice entails employing multifractionated high-dose-rate (HDR) BT, administered in 3 to 4 sessions over 3 weeks post Chemoradiation, keeping overall treatment time < 56 days. Mono-application fractionated brachytherapy accelerates the treatment timeline without escalating acute or late toxicities. Recent progress in image-guided brachytherapy in cervical cancer facilitates the attainment of optimal dose volume parameters for both the target and organs at risk. This is the first multinational, multi-institutional study comparing outcomes and toxicity of mono-application fractionated brachytherapy versus multiple-application brachytherapy in carcinoma cervix.
Materials/Methods
Enrolled 401 eligible patients with confirmed cervical cancer, FIGO stages IIA-IVA, intended definitive chemoradiation. Patients post 45-50 Gy external radiation with cisplatin either received mono-application fractionated brachytherapy or multiple-application for interstitial or intracavitary BT. Rectal and bladder doses were strictly maintained within 50% of prescription dose with adequate dosing to high-risk target volume. Demographic data, stage, histology, external radiation dose, brachytherapy dose and fractionation, D2 cc doses to bladder, rectum were recorded. Disease free survival and overall survival at 3 years were obtained along with data on acute and long-term bladder and rectal toxicities.
Results
Four hundred one patients, 203 received multiple applications spaced over 3 weeks and 198 received single application multiple deliveries < 48 hours. All patients underwent Intracavitary or Interstitial BT with most common fractionation of 7 Gyx3 or equivalent. Rectal and bladder 2 cc doses were 45% +/- 12% of prescription dose. HRCTV coverage of D90 of 95+/-7 was achieved in all cases. With a median follow up of 36 months (range = 22-37), 3 year disease-free was 0.78 and 0.76, The P value of 0.98 (> 0.05), showed difference in DFS between the two groups was not statistically significant. The 3-year overall survival was 0.72 and 0.71, P value of 0.1 (> 0.05), again statistically insignificant. Cox regression model analysis showed stage wise DFS and OS difference between the groups weren’t statistically significant, hence proving the non-inferiority. The 3 year Grade 2 or more bladder and rectal toxicity has been reported in 2.3% and 4.1% in mono application group and 2.9% and 6.3% of multi-application group, statistically insignificant, confirming the credibility of our approach.
Conclusion
Our study lays the foundation for a comprehensive investigation into the outcomes and efficacy of mono-application fractionated brachytherapy being non inferior to multiple-application with respect to outcomes and toxicity, providing valuable insights into the management of cervical cancer with reduced overall treatment time and superior resource management. Strict constraints to OARs and accuracy of image guided brachytherapy techniques, long term toxicity could be minimized.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.